Federated Hermes Inc. Buys Shares of 117,552 Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Federated Hermes Inc. bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 117,552 shares of the company's stock, valued at approximately $2,645,000. Federated Hermes Inc. owned 0.24% of Enliven Therapeutics as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ELVN. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at about $97,000. ExodusPoint Capital Management LP purchased a new position in Enliven Therapeutics during the fourth quarter valued at approximately $200,000. China Universal Asset Management Co. Ltd. lifted its holdings in Enliven Therapeutics by 14.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after acquiring an additional 1,275 shares during the period. Verition Fund Management LLC purchased a new stake in Enliven Therapeutics in the 3rd quarter worth approximately $271,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $367,000. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright increased their price target on shares of Enliven Therapeutics from $37.00 to $39.00 and gave the stock a "buy" rating in a report on Friday, March 21st.

Remove Ads

Enliven Therapeutics Price Performance

ELVN stock traded down $0.14 during mid-day trading on Tuesday, reaching $17.05. 160,946 shares of the company's stock were exchanged, compared to its average volume of 265,924. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.03. The stock's 50 day moving average is $20.20 and its 200 day moving average is $23.24. The company has a market cap of $835.52 million, a price-to-earnings ratio of -8.97 and a beta of 1.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. On average, research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Monday, January 27th. The stock was sold at an average price of $21.59, for a total value of $70,167.50. Following the transaction, the chief financial officer now owns 13,000 shares in the company, valued at approximately $280,670. This trade represents a 20.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company's stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total transaction of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company's stock, valued at $20,665,399.68. The trade was a 1.23 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 56,751 shares of company stock valued at $1,178,263 over the last ninety days. Corporate insiders own 29.20% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.